Invivyd reports sustained neutralization activity of PEMGARDA™ against dominant SARS-CoV-2 variants, supporting its ongoing emergency use status. Quiver AI Summary Invivyd, Inc. announced new in vitro ...
Invivyd, Inc. has announced new in vitro data showing that its monoclonal antibody PEMGARDA™ (pemivibart) maintains effective neutralizing activity against the prevalent LP.8.1 variant of SARS-CoV-2, ...
A recent study posted in the Cell Reports Journal reported the identification of a panel of vaccinee-derived antibodies with broad-spectrum neutralization activity. Study: Potent, omicron-neutralizing ...
In a recent study published in the Proceedings of the National Academy of Sciences, researchers explored the shortcomings in mucosal immunoglobulin A (IgA) responses induced by existing vaccines ...
According to more recent data, it has been determined that Pemgarda is likely to retain adequate neutralization activity against KP.3.1.1. The Food and Drug Administration (FDA) has updated the Fact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results